⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IFRX News
InflaRx N.V. Common Stock
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
globenewswire.com
IFRX
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
globenewswire.com
IFRX
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
globenewswire.com
IFRX
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
globenewswire.com
IFRX
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
globenewswire.com
IFRX
InflaRx to Report Full Year 2025 Results on March 19, 2026
globenewswire.com
IFRX
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
globenewswire.com
IFRX
B&F Contracting Chooses InEight Project Controls Software for End-To-End Project Visibility
globenewswire.com
IFRX
InflaRx Announces Participation in February Investor Conferences
globenewswire.com
IFRX
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
globenewswire.com
IFRX